Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
Goodyear, AZ
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
La Jolla, CA
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
Augusta, GA
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
St Louis, MO
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
Cincinnati, OH
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated:  12/4/2012
Clinical Research Facility
mi
from
San Antonio, TX
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors
Status: Enrolling
Updated: 12/4/2012
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
11C Acetate Imaging Post Prostatectomy
Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study
Status: Enrolling
Updated:  12/4/2012
Massachusetts General Hospital
mi
from
Boston, MA
11C Acetate Imaging Post Prostatectomy
Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study
Status: Enrolling
Updated: 12/4/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  12/6/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 12/6/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
University of Mississippi Medical Center Research Institute
mi
from
Jackson, MS
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
University of Mississippi Medical Center Research Institute
mi
from
Jackson, MS
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
Hershey Medical Center
mi
from
Hershey, PA
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
MBCCOP - Meharry Medical College - Nashville
mi
from
Nashville, TN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
MBCCOP - Meharry Medical College - Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
The Methodist Hospital Research Institute
mi
from
Houston, TX
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated:  12/6/2012
University of Virginia Health Sciences Center
mi
from
Charlottesville, VA
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.
Status: Enrolling
Updated: 12/6/2012
University of Virginia Health Sciences Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of LY2228820 in Patients With Advanced Cancer
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
Status: Enrolling
Updated:  12/6/2012
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of LY2228820 in Patients With Advanced Cancer
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
Status: Enrolling
Updated: 12/6/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of LY2228820 in Patients With Advanced Cancer
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
Status: Enrolling
Updated:  12/6/2012
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of LY2228820 in Patients With Advanced Cancer
A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer
Status: Enrolling
Updated: 12/6/2012
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Status: Enrolling
Updated:  12/6/2012
Tufts Medical Center
mi
from
Boston, MA
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers
Status: Enrolling
Updated: 12/6/2012
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Status: Enrolling
Updated:  12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Status: Enrolling
Updated: 12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Markers of Anthracycline-Related Cardiac Muscle Injury
Markers of Anthracycline-Related Cardiac Muscle Injury
Status: Enrolling
Updated:  12/7/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Markers of Anthracycline-Related Cardiac Muscle Injury
Markers of Anthracycline-Related Cardiac Muscle Injury
Status: Enrolling
Updated: 12/7/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Durham VA Medical Center
mi
from
Durham, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/11/2012
Duke Raleigh
mi
from
Raleigh, NC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/11/2012
Duke Raleigh
mi
from
Raleigh, NC
Click here to add this to my saved trials
Male Stress Urinary Incontinence and Sexual Health
Male Stress Urinary Incontinence and Sexual Health
Status: Enrolling
Updated:  12/11/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Male Stress Urinary Incontinence and Sexual Health
Male Stress Urinary Incontinence and Sexual Health
Status: Enrolling
Updated: 12/11/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Status: Enrolling
Updated:  12/12/2012
SUNY Upstate Medical University
mi
from
Syracuse, NY
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Status: Enrolling
Updated: 12/12/2012
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Cone Beam Computed Tomography for Breast Imaging
Cone Beam Computed Tomography for Breast Imaging
Status: Enrolling
Updated:  12/13/2012
Elizabeth Wende Breast Care
mi
from
Rochester, NY
Cone Beam Computed Tomography for Breast Imaging
Cone Beam Computed Tomography for Breast Imaging
Status: Enrolling
Updated: 12/13/2012
Elizabeth Wende Breast Care
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/14/2012
Stanford University
mi
from
Stanford, CA
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/14/2012
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated:  12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer
Status: Enrolling
Updated: 12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
Status: Enrolling
Updated:  12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
Status: Enrolling
Updated: 12/18/2012
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
Status: Enrolling
Updated:  12/18/2012
Tulane University Medical School
mi
from
New Orleans, LA
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
Status: Enrolling
Updated: 12/18/2012
Tulane University Medical School
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated:  12/19/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated: 12/19/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Mayo Clinic
mi
from
Scottsdale, AZ
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
City of Hope
mi
from
Duarte, CA
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
University of Chicago
mi
from
Chicago, IL
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/19/2012
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/19/2012
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier
Status: Enrolling
Updated:  12/28/2012
University of Colorado Denver
mi
from
Aurora, CO
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier
Status: Enrolling
Updated: 12/28/2012
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer
Status: Enrolling
Updated:  12/28/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer
Status: Enrolling
Updated: 12/28/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
Status: Enrolling
Updated:  1/2/2013
WVU Healthcare
mi
from
Morgantown, WV
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
Status: Enrolling
Updated: 1/2/2013
WVU Healthcare
mi
from
Morgantown, WV
Click here to add this to my saved trials